US5849719A
(en)
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US7935675B1
(en)
*
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
DE69535036T3
(de)
*
|
1994-07-15 |
2011-07-07 |
The University of Iowa Research Foundation, IA |
Immunomodulatorische oligonukleotide
|
US6429199B1
(en)
*
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
AU1463097A
(en)
|
1996-01-04 |
1997-08-01 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
ATE437943T1
(de)
*
|
1996-01-30 |
2009-08-15 |
Univ California |
Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
|
FR2750704B1
(fr)
|
1996-07-04 |
1998-09-25 |
Rhone Poulenc Rorer Sa |
Procede de production d'adn therapeutique
|
US5856462A
(en)
*
|
1996-09-10 |
1999-01-05 |
Hybridon Incorporated |
Oligonucleotides having modified CpG dinucleosides
|
AU768178B2
(en)
*
|
1996-10-11 |
2003-12-04 |
Regents Of The University Of California, The |
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
|
DE69733020T2
(de)
|
1996-10-11 |
2006-02-16 |
The Regents Of The University Of California, Oakland |
Immunostimulierende oligonucleotidekonjugate
|
EP0855184A1
(de)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
|
AU738513B2
(en)
|
1997-02-28 |
2001-09-20 |
University Of Iowa Research Foundation, The |
Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
|
PT1005368E
(pt)
*
|
1997-03-10 |
2009-11-19 |
Coley Pharm Gmbh |
Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
DE69841002D1
(de)
|
1997-05-14 |
2009-09-03 |
Univ British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
JP2001526688A
(ja)
*
|
1997-05-19 |
2001-12-18 |
メルク エンド カンパニー インコーポレーテッド |
オリゴヌクレオチドアジュバント
|
AU7690898A
(en)
|
1997-05-20 |
1998-12-11 |
Ottawa Civic Hospital Loeb Research Institute |
Vectors and methods for immunization or therapeutic protocols
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
EP1374894A3
(de)
*
|
1997-06-06 |
2004-09-22 |
Dynavax Technologies Corporation |
Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
DE69819150T3
(de)
|
1997-06-06 |
2007-12-20 |
Dynavax Technologies Corp., San Diego |
Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
|
PT1009413E
(pt)
*
|
1997-09-05 |
2007-05-31 |
Univ California |
Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
PT1053325E
(pt)
|
1998-02-05 |
2006-05-31 |
Glaxosmithkline Biolog Sa |
Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
WO1999051259A2
(en)
*
|
1998-04-03 |
1999-10-14 |
University Of Iowa Research Foundation |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
CA2325939A1
(en)
*
|
1998-04-09 |
1999-10-21 |
Martin Friede |
Vaccine
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
WO1999056755A1
(en)
*
|
1998-05-06 |
1999-11-11 |
University Of Iowa Research Foundation |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
IL139646A0
(en)
*
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
AU761879B2
(en)
|
1998-05-19 |
2003-06-12 |
Research Development Foundation |
Triterpene compositions and methods for use thereof
|
AU761899B2
(en)
*
|
1998-05-22 |
2003-06-12 |
Ottawa Health Research Institute |
Methods and products for inducing mucosal immunity
|
US6881561B1
(en)
|
1998-05-27 |
2005-04-19 |
Cheil Jedang Corporation |
Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
|
KR19990086271A
(ko)
*
|
1998-05-27 |
1999-12-15 |
손경식 |
면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
WO2000006588A1
(en)
*
|
1998-07-27 |
2000-02-10 |
University Of Iowa Research Foundation |
STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
|
WO2000006602A1
(fr)
|
1998-07-31 |
2000-02-10 |
Haruo Sugiyama |
Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1
|
WO2000008051A2
(en)
|
1998-08-07 |
2000-02-17 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
CA2340174C
(en)
*
|
1998-08-10 |
2011-01-04 |
Aquila Biopharmaceuticals, Inc. |
Compositions of cpg and saponin adjuvants and methods thereof
|
EP1832657B1
(de)
*
|
1998-09-09 |
2012-10-24 |
Genzyme Corporation |
Methylierung von Plasmid-Vektoren
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
FR2783170B1
(fr)
*
|
1998-09-11 |
2004-07-16 |
Pasteur Merieux Serums Vacc |
Emulsion immunostimulante
|
AU766492B2
(en)
*
|
1998-09-18 |
2003-10-16 |
Dynavax Technologies Corporation |
Methods of treating IgE-associated disorders and compositions for use therein
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
CA2346452A1
(en)
*
|
1998-10-05 |
2000-04-13 |
The Regents Of The University Of California |
Methods and adjuvants for stimulating mucosal immunity
|
DE69935606T9
(de)
|
1998-10-16 |
2021-03-11 |
Glaxosmithkline Biologicals S.A. |
Adjuvanzsysteme und impfstoffe
|
CA2746535A1
(en)
|
1998-12-08 |
2000-06-15 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
EP2374889A3
(de)
|
1998-12-08 |
2012-02-22 |
GlaxoSmithKline Biologicals SA |
Neue Verbindungen
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
JP2002536344A
(ja)
*
|
1999-02-05 |
2002-10-29 |
ジエンザイム コーポレイション |
抗腫瘍免疫を発生させるためのカチオン性脂質の使用
|
JP5084984B2
(ja)
|
1999-02-17 |
2012-11-28 |
シーエスエル、リミテッド |
免疫原複合体およびそれに関する方法
|
AU2457100A
(en)
|
1999-02-26 |
2000-09-14 |
Chiron S.P.A. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
|
DE60020677T2
(de)
|
1999-02-26 |
2006-05-04 |
Chiron Corp., Emeryville |
Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
|
EP2163628A3
(de)
|
1999-03-12 |
2010-06-02 |
GlaxoSmithKline Biologicals S.A. |
Antigene Polypeptide aus Neisseria Meningitidis, dafür kodierende Polynukleotide und entsprechende schützende Antikörper
|
JP2000262247A
(ja)
*
|
1999-03-19 |
2000-09-26 |
Asama Kasei Kk |
免疫調節剤、免疫調節食品および免疫調節飼料
|
CZ303653B6
(cs)
|
1999-03-19 |
2013-01-30 |
Smithkline Beecham Biologicals S. A. |
Imunogenní prostredek
|
FR2790955B1
(fr)
*
|
1999-03-19 |
2003-01-17 |
Assist Publ Hopitaux De Paris |
Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
EA005140B1
(ru)
|
1999-04-02 |
2004-12-30 |
Корикса Корпорейшн |
Соединения и способы для лечения и диагностики рака легкого
|
EP1176966B1
(de)
|
1999-04-12 |
2013-04-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
ES2228497T3
(es)
*
|
1999-04-19 |
2005-04-16 |
Glaxosmithkline Biologicals S.A. |
Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
DE60013591T2
(de)
*
|
1999-04-29 |
2005-02-03 |
Coley Pharmaceutical Gmbh |
Screening nach modulatoren der funktion von immunstimulatorischer dna
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
WO2001000232A2
(en)
*
|
1999-06-29 |
2001-01-04 |
Smithkline Beecham Biologicals S.A. |
Use of cpg as an adjuvant for hiv vaccine
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
FR2795963A1
(fr)
*
|
1999-07-08 |
2001-01-12 |
Pasteur Merieux Serums Vacc |
Polynucleotide immunostimulant
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
US20050226890A1
(en)
*
|
1999-08-12 |
2005-10-13 |
Cohen David I |
Tat-based vaccine compositions and methods of making and using same
|
JP2003507341A
(ja)
*
|
1999-08-19 |
2003-02-25 |
ダイナバックス テクノロジーズ コーポレイション |
免疫刺激配列およびそれを使用するための組成物を用いて免疫応答を調節するための方法およびそれを使用するための組成物
|
CA2382611A1
(en)
*
|
1999-08-27 |
2001-03-08 |
Inex Pharmaceuticals Corp. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
TR200503031T2
(tr)
*
|
1999-09-25 |
2005-09-21 |
University Of Iowa Research Foundation |
İmmünostimülatör nükleik asitler
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
AU2593701A
(en)
*
|
1999-12-21 |
2001-07-03 |
Regents Of The University Of California, The |
Method for preventing an anaphylactic reaction
|
ATE378348T1
(de)
|
2000-01-14 |
2007-11-15 |
Us Health |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
AT409085B
(de)
*
|
2000-01-28 |
2002-05-27 |
Cistem Biotechnologies Gmbh |
Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
|
AU2001231245A1
(en)
*
|
2000-01-31 |
2001-08-07 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
FR2805264B1
(fr)
*
|
2000-02-18 |
2002-04-12 |
Aventis Pasteur |
Oligonucleotides immunostimulants
|
FR2805265B1
(fr)
*
|
2000-02-18 |
2002-04-12 |
Aventis Pasteur |
Oligonucleotides immunostimulants
|
PL209127B1
(pl)
|
2000-02-23 |
2011-07-29 |
Smithkline Beecham Biolog |
Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US6613751B2
(en)
|
2000-02-23 |
2003-09-02 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US7129222B2
(en)
*
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
AU2001251407A1
(en)
*
|
2000-04-07 |
2001-10-23 |
The Regents Of The University Of California |
Synergistic improvements to polynucleotide vaccines
|
DE60133190T2
(de)
|
2000-04-21 |
2009-04-02 |
CORIXA CORP., Wilmington |
Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
|
EP1282702B1
(de)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
PL206832B1
(pl)
|
2000-05-19 |
2010-09-30 |
Corixa Corp |
Zastosowanie związków opartych na mono- i disacharydach
|
CA2413959C
(en)
|
2000-06-20 |
2015-07-07 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
CA2410371C
(en)
|
2000-06-22 |
2015-11-17 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
DE60134158D1
(de)
|
2000-06-28 |
2008-07-03 |
Corixa Corp |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
PL393584A1
(pl)
|
2000-06-29 |
2011-05-23 |
Glaxosmithkline Biologicals S.A. |
Szczepionka
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
WO2006033665A1
(en)
*
|
2004-03-16 |
2006-03-30 |
Inist Inc. |
Tat-based vaccine compositions and methods of making and using same
|
AU2001285421A1
(en)
*
|
2000-08-10 |
2002-02-18 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Vaccine against rsv
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
WO2005090392A1
(en)
*
|
2004-03-16 |
2005-09-29 |
Inist Inc. |
Tat-based tolerogen compositions and methods of making and using same
|
JP2005503320A
(ja)
*
|
2000-08-25 |
2005-02-03 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
CpG−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
EP1366077B1
(de)
*
|
2000-09-15 |
2011-05-25 |
Coley Pharmaceutical GmbH |
Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
|
SI2266603T1
(sl)
|
2000-10-18 |
2012-12-31 |
Glaxosmithkline Biologicals S.A. |
Tumorska cepiva
|
SG165981A1
(en)
|
2000-10-27 |
2010-11-29 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
EP1350262B8
(de)
*
|
2000-12-08 |
2008-08-13 |
Coley Pharmaceuticals GmbH |
Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
CN1293192C
(zh)
*
|
2000-12-27 |
2007-01-03 |
戴纳瓦克斯技术公司 |
免疫调节性多核苷酸及其使用方法
|
CN1496267A
(zh)
*
|
2001-01-12 |
2004-05-12 |
������ҩ��ʽ���� |
微生物感染防御剂
|
JPWO2002055091A1
(ja)
*
|
2001-01-12 |
2004-05-13 |
天藤製薬株式会社 |
抗アレルギー剤
|
US7128911B2
(en)
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
US20040116520A1
(en)
*
|
2001-01-24 |
2004-06-17 |
Amato Pharmaceutical Products, Ltd. |
Anti-stress agents
|
DE10105234A1
(de)
|
2001-02-02 |
2002-08-29 |
Schoeller Textil Ag Sevelen |
Textile Fläche
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
BRPI0208183B8
(pt)
|
2001-03-22 |
2021-05-25 |
Sugiyama Haruo |
peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
ES2288555T3
(es)
|
2001-05-21 |
2008-01-16 |
Intercell Ag |
Moleculas de oligodesoxinucleotidos inmunoestimuladores.
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
WO2003000922A2
(en)
*
|
2001-06-21 |
2003-01-03 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
CZ20033515A3
(cs)
*
|
2001-06-29 |
2005-01-12 |
Chiron Corporation |
Kompozice vakcíny HCV E1E2
|
CA2452382A1
(en)
|
2001-07-10 |
2003-01-23 |
Corixa Corporation |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
US20030148316A1
(en)
*
|
2001-08-01 |
2003-08-07 |
Lipford Grayson B. |
Methods and compositions relating to plasmacytoid dendritic cells
|
CA2456193A1
(en)
*
|
2001-08-03 |
2003-03-27 |
Medarex, Inc. |
Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
|
AU2002326561B2
(en)
|
2001-08-07 |
2008-04-03 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, formulations, and methods for use thereof
|
US7354909B2
(en)
*
|
2001-08-14 |
2008-04-08 |
The United States Of America As Represented By Secretary Of The Department Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
PT1446162E
(pt)
|
2001-08-17 |
2009-01-27 |
Coley Pharm Gmbh |
Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
|
EP2518142B1
(de)
|
2001-08-24 |
2015-07-15 |
UVic Industry Partnerships Inc. |
Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs
|
MXPA04001972A
(es)
*
|
2001-08-30 |
2005-02-17 |
3M Innovative Properties Co |
Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune.
|
CN1575184A
(zh)
*
|
2001-09-07 |
2005-02-02 |
波士顿大学理事会 |
治疗免疫复合物相关疾病的方法和组合物
|
CA2492826C
(en)
|
2001-09-14 |
2016-12-13 |
Cytos Biotechnology Ag |
Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
|
JP4360906B2
(ja)
*
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
|
BR0212619A
(pt)
|
2001-09-20 |
2004-08-17 |
Glaxo Group Ltd |
Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
|
WO2003027313A2
(en)
|
2001-09-24 |
2003-04-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
JPWO2003028758A1
(ja)
*
|
2001-09-28 |
2005-01-13 |
治夫 杉山 |
抗原特異的t細胞の誘導方法
|
US8735357B2
(en)
|
2001-09-28 |
2014-05-27 |
International Institute Of Cancer Immunology, Inc. |
Method of inducing antigen-specific T cells
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
JP2005505284A
(ja)
*
|
2001-10-05 |
2005-02-24 |
コリー ファーマスーティカル ゲーエムベーハー |
Toll様受容体3シグナリングアゴニストおよびアンタゴニススト
|
US20030139364A1
(en)
*
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
TW200303759A
(en)
*
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
JP2005519035A
(ja)
*
|
2001-12-07 |
2005-06-30 |
インターツェル・アクチェンゲゼルシャフト |
免疫促進性オリゴデオキシヌクレオチド
|
EP1465634B1
(de)
|
2001-12-12 |
2014-10-22 |
The Government of the United States of America, as represented by the Secretary Department of Health and Human Services |
Verfahren zur verwendung adenosinrezeptorinhibitoren zur verstärkung der immunantwort und entzündung
|
WO2003053220A2
(en)
|
2001-12-17 |
2003-07-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
AU2002357359B2
(en)
*
|
2001-12-21 |
2009-01-08 |
Csl Limited |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
US20040034223A1
(en)
*
|
2002-02-07 |
2004-02-19 |
Covalent Partners, Llc. |
Amphiphilic molecular modules and constructs based thereon
|
US7432371B2
(en)
*
|
2002-02-07 |
2008-10-07 |
Covalent Partners, Llc |
Nanofilm and membrane compositions
|
US8088388B2
(en)
*
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
AU2003215316A1
(en)
|
2002-02-20 |
2003-09-09 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
AU2003218181A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Multicell Immunotherapeutics, Inc. |
Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
|
EP2258712A3
(de)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
NZ573064A
(en)
*
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
CN1665531A
(zh)
*
|
2002-05-10 |
2005-09-07 |
伊内克斯药物公司 |
甲基化的免疫刺激性寡核苷酸和利用这些寡核苷酸的方法
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
KR100456681B1
(ko)
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
CA2388049A1
(en)
*
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
US20040009949A1
(en)
*
|
2002-06-05 |
2004-01-15 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
|
CA2488856A1
(en)
*
|
2002-06-20 |
2003-12-31 |
Cytos Biotechnology Ag |
Packaged virus-like particles for use as adjuvants: method of preparation and use
|
CA2490804C
(en)
|
2002-06-28 |
2016-12-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
WO2004007743A2
(en)
*
|
2002-07-17 |
2004-01-22 |
Coley Pharmaceutical Gmbh |
Use of cpg nucleic acids in prion-disease
|
DK1523582T3
(da)
|
2002-07-18 |
2009-03-02 |
Univ Washington |
Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
|
WO2004011650A2
(en)
|
2002-07-24 |
2004-02-05 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
CA2489030A1
(en)
|
2002-08-02 |
2004-02-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
|
ES2355819T3
(es)
|
2002-08-15 |
2011-03-31 |
3M Innovative Properties Company |
Composiciones inmunoestimuladoras y métodos para estimular una respuesta inmune.
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CA2484339A1
(en)
|
2002-09-13 |
2004-03-25 |
Intercell Ag |
Method for isolating hepatitis c virus peptides
|
US20040106741A1
(en)
*
|
2002-09-17 |
2004-06-03 |
Kriesel Joshua W. |
Nanofilm compositions with polymeric components
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
AU2003268737A1
(en)
*
|
2002-10-02 |
2004-04-23 |
Mochida Pharmaceutical Co., Ltd. |
Novel method of constructing monoclonal antibody
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
WO2004035618A2
(en)
|
2002-10-15 |
2004-04-29 |
Intercell Ag |
Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
|
JP5404990B2
(ja)
|
2002-10-23 |
2014-02-05 |
グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム |
マラリアに対するワクチン接種の方法
|
WO2004037321A2
(en)
*
|
2002-10-25 |
2004-05-06 |
University Of Connecticut Health Center |
Immunotherapy of cancer through controlled cell lysis
|
EP2241325B1
(de)
*
|
2002-10-29 |
2012-02-08 |
Coley Pharmaceutical Group, Inc. |
Verwendung von CPG Oligonukleotide zur Behandlung von Hepatitis C Virus Infektion
|
EP1572122A4
(de)
*
|
2002-11-01 |
2008-04-09 |
Us Gov Health & Human Serv |
Verfahren zur vorbeugung gegen infektionen von bioterrorismus-agentien mit immunstimulierenden cpg-oligonukleotiden
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
JP4750419B2
(ja)
*
|
2002-11-21 |
2011-08-17 |
ベイヒル セラピューティクス インコーポレーティッド |
疾患を予防および治療するための方法および免疫調節核酸組成物
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US20050287170A1
(en)
*
|
2002-12-11 |
2005-12-29 |
Hawaii Biotech, Inc. |
Subunit vaccine against West Nile viral infection
|
US7956043B2
(en)
|
2002-12-11 |
2011-06-07 |
Coley Pharmaceutical Group, Inc. |
5′ CpG nucleic acids and methods of use
|
US20040213808A1
(en)
*
|
2002-12-11 |
2004-10-28 |
Michael Lieberman |
Recombinant vaccine against flavivirus infection
|
KR100525321B1
(ko)
*
|
2002-12-13 |
2005-11-02 |
안웅식 |
파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
|
EP1625140A4
(de)
*
|
2002-12-23 |
2008-06-18 |
Dynavax Tech Corp |
Verzweigte immunmodulatorische verbindungen und anwendungsverfahren dafür
|
NZ541027A
(en)
|
2002-12-23 |
2008-04-30 |
Dynavax Tech Corp |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
CA2511538C
(en)
|
2002-12-30 |
2013-11-26 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
ES2531125T3
(es)
|
2003-02-03 |
2015-03-10 |
Ibio Inc |
Sistema para la expresión de genes en plantas
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
US8877204B2
(en)
|
2003-02-20 |
2014-11-04 |
University Of Connecticut Health Center |
Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
|
GB2398783A
(en)
|
2003-02-26 |
2004-09-01 |
Antonio Lanzavecchia |
A method for producing immortalised human B memory lymphocytes
|
WO2004075865A2
(en)
*
|
2003-02-27 |
2004-09-10 |
3M Innovative Properties Company |
Selective modulation of tlr-mediated biological activity
|
AU2004218349A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
EP2287312A1
(de)
|
2003-03-04 |
2011-02-23 |
Intercell AG |
Streptococcus-pyogenes-Antigene
|
JP2006520245A
(ja)
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
MXPA05009694A
(es)
*
|
2003-03-13 |
2005-10-20 |
3M Innovative Properties Co |
Metodos para mejorar la calidad de la piel.
|
CA2517673C
(en)
|
2003-03-24 |
2013-08-13 |
Intercell Ag |
Improved vaccines for preventing viral infection
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
WO2004084940A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
|
AU2004225480A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Multicell Immunotherapeutics, Inc. |
Selected RNA motifs to include cell death and/or apoptosis
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ATE449177T1
(de)
|
2003-03-31 |
2009-12-15 |
Intercell Ag |
Staphylococcus epidermidis antigene
|
EP1608403A2
(de)
*
|
2003-04-02 |
2005-12-28 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
|
JP2007500210A
(ja)
*
|
2003-04-10 |
2007-01-11 |
スリーエム イノベイティブ プロパティズ カンパニー |
金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
SE0301109D0
(sv)
*
|
2003-04-14 |
2003-04-14 |
Mallen Huang |
Nucleotide vaccine composition
|
EP2298934A1
(de)
|
2003-04-15 |
2011-03-23 |
Intercell AG |
S. pneumoniae Antigene
|
EP1617845A4
(de)
*
|
2003-04-28 |
2006-09-20 |
3M Innovative Properties Co |
Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
|
CN101864431A
(zh)
|
2003-05-07 |
2010-10-20 |
英特塞尔股份公司 |
无乳链球菌抗原ⅰ和ⅱ
|
AU2004238139B2
(en)
*
|
2003-05-15 |
2009-12-03 |
Japan Science And Technology Agency |
Immunostimulating Agents
|
CN103074316B
(zh)
|
2003-05-22 |
2015-10-21 |
美国弗劳恩霍夫股份有限公司 |
用于表达、传递及纯化目标多肽的重组载体分子
|
JP2008500007A
(ja)
|
2003-05-30 |
2008-01-10 |
インターツェル・アクチェンゲゼルシャフト |
腸球菌抗原
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US7803386B2
(en)
|
2003-06-05 |
2010-09-28 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
|
KR20060016817A
(ko)
*
|
2003-06-20 |
2006-02-22 |
콜리 파마슈티칼 게엠베하 |
소분자 톨-유사 수용체 (tlr) 길항제
|
KR20060031607A
(ko)
*
|
2003-07-10 |
2006-04-12 |
사이토스 바이오테크놀로지 아게 |
패킹된 바이러스-양 입자
|
US20050013812A1
(en)
*
|
2003-07-14 |
2005-01-20 |
Dow Steven W. |
Vaccines using pattern recognition receptor-ligand:lipid complexes
|
WO2005016275A2
(en)
*
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
MXPA06001669A
(es)
*
|
2003-08-12 |
2006-04-28 |
3M Innovative Properties Co |
Compuestos que contienen imidazo-oxima sustituidos.
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
EP1658076B1
(de)
*
|
2003-08-27 |
2013-03-06 |
3M Innovative Properties Company |
Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
|
EP1663222A4
(de)
*
|
2003-09-02 |
2008-05-21 |
3M Innovative Properties Co |
Verfahren im zusammenhang mit der behandlung von schleimhauterkrankungen
|
EP1660026A4
(de)
*
|
2003-09-05 |
2008-07-16 |
3M Innovative Properties Co |
Behandlung von cd5+ b-zell-lyphom
|
AU2004274430A1
(en)
|
2003-09-12 |
2005-03-31 |
Antigenics, Inc. |
Vaccine for treatment and prevention of herpes simplex virus infection
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
AU2004277342B2
(en)
|
2003-10-02 |
2010-12-16 |
Glaxosmithkline Biologicals S.A. |
Pertussis antigens and use thereof in vaccination
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
RU2412942C2
(ru)
*
|
2003-10-03 |
2011-02-27 |
3М Инновейтив Пропертиз Компани |
Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
|
JP2007509040A
(ja)
*
|
2003-10-11 |
2007-04-12 |
イネックス ファーマシューティカルズ コーポレイション |
先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
|
CA2540949A1
(en)
*
|
2003-10-30 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
WO2005041891A2
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
AU2004291122A1
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
AU2004291101A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
NZ547467A
(en)
*
|
2003-11-25 |
2010-06-25 |
3M Innovative Properties Co |
Substituted imidazo ring system and methods
|
US20050287118A1
(en)
*
|
2003-11-26 |
2005-12-29 |
Epitomics, Inc. |
Bacterial plasmid with immunological adjuvant function and uses thereof
|
US20050277127A1
(en)
*
|
2003-11-26 |
2005-12-15 |
Epitomics, Inc. |
High-throughput method of DNA immunogen preparation and immunization
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
US7399467B2
(en)
|
2003-12-23 |
2008-07-15 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of HPV and methods of their use
|
JP4817599B2
(ja)
*
|
2003-12-25 |
2011-11-16 |
独立行政法人科学技術振興機構 |
免疫活性増強剤とこれを用いた免疫活性の増強方法
|
JP2007517035A
(ja)
*
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
WO2005066169A2
(en)
*
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
WO2005072290A2
(en)
*
|
2004-01-23 |
2005-08-11 |
Joslin Diabetes Center |
Methods of treating, reducing, or preventing autoimmune conditions
|
US8080253B2
(en)
|
2004-02-05 |
2011-12-20 |
The Ohio State University Research Foundation |
Chimeric VEGF peptides
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
EP1720568A2
(de)
|
2004-02-19 |
2006-11-15 |
Coley Pharmaceutical Group, Inc. |
Immunstimulatorische virale rna-oligonucleotide
|
CA2559458A1
(en)
|
2004-03-19 |
2005-10-06 |
Xiu-Min Li |
Herbal therapy for the treatment of food allergy
|
US8697873B2
(en)
*
|
2004-03-24 |
2014-04-15 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
US20070166384A1
(en)
*
|
2004-04-09 |
2007-07-19 |
Zarraga Isidro Angelo E |
Methods , composition and preparations for delivery of immune response modifiers
|
US20060051374A1
(en)
*
|
2004-04-28 |
2006-03-09 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
AU2005247341B2
(en)
|
2004-05-06 |
2008-05-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
CA2567597C
(en)
|
2004-05-25 |
2014-03-18 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
AU2005294805B2
(en)
|
2004-05-28 |
2012-02-16 |
Oryxe |
A mixture for transdermal delivery of low and high molecular weight compounds
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
WO2006009826A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US20070259881A1
(en)
*
|
2004-06-18 |
2007-11-08 |
Dellaria Joseph F Jr |
Substituted Imidazo Ring Systems and Methods
|
US7897609B2
(en)
*
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
NZ553244A
(en)
*
|
2004-07-18 |
2009-10-30 |
Csl Ltd |
Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
|
DK2412728T3
(en)
|
2004-08-03 |
2015-04-07 |
Innate Pharma |
Therapeutic compositions for cancer, that target 4Ig-B7-H3
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
EP1791559A2
(de)
|
2004-09-22 |
2007-06-06 |
GlaxoSmithKline Biologicals SA |
Immunogene zusammensetzung
|
US9573979B2
(en)
|
2004-09-24 |
2017-02-21 |
Susanne Modrow |
Modified VP1-capsid protein of parvovirus B19
|
JP2008000001A
(ja)
*
|
2004-09-30 |
2008-01-10 |
Osaka Univ |
免疫刺激オリゴヌクレオチドおよびその医薬用途
|
DK3312272T3
(da)
|
2004-10-08 |
2019-12-02 |
Us Gov Health & Human Services |
Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
WO2006065549A2
(en)
|
2004-12-03 |
2006-06-22 |
Medical University Of Ohio |
Attenuated vaccine useful for immunizations against coccidioides spp. infections
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
JP5313502B2
(ja)
|
2004-12-30 |
2013-10-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
PT1830876E
(pt)
|
2004-12-30 |
2015-07-13 |
Meda Ab |
Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama
|
CA2592904C
(en)
|
2004-12-30 |
2015-04-07 |
3M Innovative Properties Company |
Chiral fused [1,2]imidazo[4,5-c] ring compounds
|
CA2590974C
(en)
|
2005-01-27 |
2017-10-03 |
Children's Hospital & Research Center At Oakland |
Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
US9248127B2
(en)
*
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
AU2006216493A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory oligonucleotides
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US8101345B1
(en)
|
2005-03-25 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Proinflammatory nucleic acids
|
CN101184504A
(zh)
|
2005-03-31 |
2008-05-21 |
葛兰素史密丝克莱恩生物有限公司 |
针对衣原体感染的疫苗
|
EP1863814A1
(de)
|
2005-04-01 |
2007-12-12 |
Coley Pharmaceutical Group, Inc. |
1-substitutierte pyrazolo-(3,4-c)-ringverbindungen als cytokinbiosynthese-modulatoren für die behandlung viraler infektionen und neoplastischer erkrankungen
|
EP1869043A2
(de)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridin-1,4-diamine und analoge davon
|
RU2007141402A
(ru)
*
|
2005-04-08 |
2009-05-20 |
Коли Фармасьютикал Груп, Инк. (Us) |
Способы лечения астмы, осложненной инфекционными заболеваниями
|
EP2842559A3
(de)
*
|
2005-04-08 |
2015-03-18 |
Chimerix, Inc. |
Verbindungen, Zusammensetzungen und Verfahren zur Behandlung viraler Infektionen und anderer Erkrankungen
|
EP1868628B1
(de)
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Verbindungen, zusammensetzungen und verfahren zur behandlung von pockenvirus-infektionen
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
CA2609788A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
CN106390108B
(zh)
|
2005-04-29 |
2020-09-08 |
葛兰素史密丝克莱恩生物有限公司 |
用于预防或治疗结核分枝杆菌感染的新方法
|
ES2366380T3
(es)
|
2005-06-14 |
2011-10-19 |
Protox Therapeutics Incorporated |
Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.
|
WO2006138675A2
(en)
|
2005-06-15 |
2006-12-28 |
The Ohio State University Research Foundation |
Her-2 peptides
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
DE602006008473D1
(de)
|
2005-07-01 |
2009-09-24 |
Index Pharmaceuticals Ab |
Modulierung der reaktion auf steroide
|
AU2006266503B2
(en)
|
2005-07-01 |
2011-12-08 |
Index Pharmaceuticals Ab |
Immunostimulatory method
|
CA2614320A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Coley Pharmaceutical Group, Inc. |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
US20080206276A1
(en)
*
|
2005-07-08 |
2008-08-28 |
Michael Otto |
Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
|
WO2007008780A2
(en)
|
2005-07-11 |
2007-01-18 |
Globeimmune, Inc. |
Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
|
CA2616859C
(en)
|
2005-08-03 |
2015-04-14 |
Fraunhofer Usa, Inc. |
Compositions and methods for production of immunoglobulins
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
SG165394A1
(en)
*
|
2005-09-16 |
2010-10-28 |
Coley Pharm Gmbh |
Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
|
CA2622679A1
(en)
*
|
2005-09-16 |
2007-08-09 |
Coley Pharmaceutical Gmbh |
Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
|
US20070081972A1
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
EP1940472A1
(de)
|
2005-10-28 |
2008-07-09 |
Index Pharmaceuticals AB |
Zusammensetzung und verfahren zur prävention, behandlung und/oder linderung einer entzündlichen erkrankung
|
WO2007062107A2
(en)
*
|
2005-11-25 |
2007-05-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory oligoribonucleotides
|
WO2007070660A2
(en)
|
2005-12-13 |
2007-06-21 |
President And Fellows Of Harvard College |
Scaffolds for cell transplantation
|
RU2451523C2
(ru)
|
2005-12-14 |
2012-05-27 |
Цитос Биотехнологи Аг |
Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
|
DK2384765T3
(en)
|
2005-12-22 |
2017-01-09 |
Glaxosmithkline Biologicals Sa |
Vaccine against Streptococcus pneumoniae.
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1981905B1
(de)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia-impfstoff
|
CN104436180B
(zh)
|
2006-01-17 |
2021-08-31 |
阿恩·福斯格伦 |
新的表面外露流感嗜血菌蛋白质(蛋白质E;pE)
|
EP1984405A4
(de)
|
2006-02-13 |
2010-06-30 |
Fraunhofer Usa Inc |
Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
|
CA2642152C
(en)
|
2006-02-15 |
2016-11-01 |
Coley Pharmaceutical Gmbh |
Compositions and methods for oligonucleotide formulations
|
US8951528B2
(en)
*
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
EP2397856B1
(de)
|
2006-03-14 |
2013-11-13 |
Oregon Health and Science University |
Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
|
CN103169960A
(zh)
|
2006-03-30 |
2013-06-26 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
EP2017281A4
(de)
|
2006-04-14 |
2012-03-14 |
Kyowa Hakko Kirin Co Ltd |
Agonisten am toll-like receptor 9
|
EP2034015B1
(de)
|
2006-05-31 |
2012-07-11 |
Toray Industries, Inc. |
Immunstimulierendes oligonukleotid und pharmazeutische anwendung davon
|
EP2390362A1
(de)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals SA |
Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IRF1
|
KR100906970B1
(ko)
|
2006-06-03 |
2009-07-10 |
주식회사 바이오씨에스 |
피부 면역질환에 대한 CpG 올리고데옥시뉴클레오티드의치료학적 용도
|
US20080026986A1
(en)
*
|
2006-06-05 |
2008-01-31 |
Rong-Fu Wang |
Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
|
MX2008015529A
(es)
|
2006-06-12 |
2009-01-13 |
Cytos Biotechnology Ag |
Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
|
JP5275983B2
(ja)
|
2006-06-12 |
2013-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
EP2292647A3
(de)
|
2006-07-07 |
2011-06-08 |
Intercell AG |
Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
WO2008094183A2
(en)
*
|
2006-07-11 |
2008-08-07 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
WO2008014979A2
(en)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
DE102006035618A1
(de)
*
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
BRPI0716518B8
(pt)
|
2006-09-07 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
vacina de ipv e uso da mesma
|
CA2661224A1
(en)
|
2006-09-15 |
2008-03-20 |
Intercell Ag |
Borrelia antigens
|
CN101516396B
(zh)
|
2006-09-26 |
2013-10-09 |
传染性疾病研究院 |
包含合成佐剂的疫苗组合物
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
RU2009115687A
(ru)
*
|
2006-10-26 |
2010-11-10 |
Коли Фармасьютикал Гмбх (De) |
Олигорибонуклеотиды и их применения
|
EP3564674B1
(de)
|
2006-11-01 |
2021-08-25 |
Ventana Medical Systems, Inc. |
Haptene, haptenkonjugate, zusammensetzungen daraus und verfahren zu deren herstellung und verwendung
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
WO2008073661A2
(en)
|
2006-11-09 |
2008-06-19 |
Dynavax Technologies Corporation |
Long term disease modification using immunostimulatory oligonucleotides
|
EP1923069A1
(de)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
CA2675379A1
(en)
|
2007-01-12 |
2008-07-17 |
Intercell Ag |
Protective proteins of s. agalactiae, combinations thereof and methods of using the same
|
EP2918598B1
(de)
|
2007-02-28 |
2019-01-30 |
The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyurie-Polypeptide und Verwendungsverfahren
|
CN105106971A
(zh)
|
2007-03-02 |
2015-12-02 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物及其在刺激免疫反应中的用途
|
US20090041809A1
(en)
*
|
2007-03-07 |
2009-02-12 |
Nventa Biopharmaceuticals Corporation |
Double-stranded locked nucleic acid compositions
|
WO2008115610A1
(en)
|
2007-03-19 |
2008-09-25 |
Globeimmune, Inc. |
Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
|
ES2621211T3
(es)
|
2007-04-04 |
2017-07-03 |
Infectious Disease Research Institute |
Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
CN101687024A
(zh)
|
2007-04-28 |
2010-03-31 |
美国弗劳恩霍夫股份有限公司 |
锥虫抗原、疫苗组合物和相关方法
|
CL2008001258A1
(es)
|
2007-05-02 |
2009-01-16 |
Glaxosmithkline Biologicals Sa |
Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
|
EP2497779A1
(de)
|
2007-05-02 |
2012-09-12 |
Intercell AG |
Klebsiella-Antigene
|
US8309529B2
(en)
*
|
2007-05-04 |
2012-11-13 |
Index Pharmaceuticals Ab |
Tumour growth inhibitory compounds and methods of their use
|
CA2687441A1
(en)
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Group, Inc. |
Class a oligonucleotides with immunostimulatory potency
|
PL2170353T3
(pl)
*
|
2007-05-18 |
2015-10-30 |
Adiutide Pharmaceuticals Gmbh |
Modyfikowane fosforanami analogi oligonukleotydów wykazujące aktywność immunostymulującą
|
EP3561513A1
(de)
|
2007-05-23 |
2019-10-30 |
Ventana Medical Systems, Inc. |
Polymere träger für immunhistochemie und in-situ-hybridisierung
|
BRPI0811228A2
(pt)
|
2007-05-24 |
2014-10-21 |
Glaxonsmithkline Biolog S A |
Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
|
ES2602610T3
(es)
|
2007-05-31 |
2017-02-21 |
Medigene Ag |
Proteína estructural mutada de un parvovirus
|
EP2012122A1
(de)
|
2007-07-06 |
2009-01-07 |
Medigene AG |
Strukturproteine von mutierten Parvoviren als Impfstoffe
|
JP2010530229A
(ja)
|
2007-06-18 |
2010-09-09 |
インターセル アーゲー |
クラミジア属の抗原
|
JP2010531330A
(ja)
|
2007-06-26 |
2010-09-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
WO2009009759A2
(en)
|
2007-07-11 |
2009-01-15 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
JP5654345B2
(ja)
|
2007-08-02 |
2015-01-14 |
ビオンドヴァックス ファーマシューティカルズ リミテッド |
多量体マルチエピトープインフルエンザワクチン
|
CA2695421A1
(en)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
US7879812B2
(en)
|
2007-08-06 |
2011-02-01 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides and methods of use therefor
|
BRPI0815199A2
(pt)
|
2007-08-13 |
2015-03-31 |
Glaxosmithkline Biolog Sa |
Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum
|
BRPI0814899A2
(pt)
*
|
2007-08-21 |
2015-02-03 |
Dynavax Tech Corp |
Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
|
EP2185160B1
(de)
|
2007-08-31 |
2019-02-13 |
Neurimmune Holding AG |
Verfahren zur bereitstellung patientenspezifischer immunreaktionen bei amyloidose- und proteinaggregationserkrankungen
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
US9050280B2
(en)
|
2007-09-17 |
2015-06-09 |
Mdxhealth Sa |
Methylation detection of MGMT
|
CN101820908A
(zh)
|
2007-10-09 |
2010-09-01 |
科利制药公司 |
包含改性糖部分的免疫刺激寡核苷酸类似物
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
CA2703519C
(en)
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
EP2227250A4
(de)
|
2007-12-03 |
2011-07-06 |
Harvard College |
Chlamydia-antigene
|
ES2664753T3
(es)
|
2007-12-07 |
2018-04-23 |
Glaxosmithkline Biologicals Sa |
Composiciones de inducción de respuestas inmunes
|
EP3508505A1
(de)
|
2007-12-24 |
2019-07-10 |
ID Biomedical Corporation of Quebec |
Rekombinante rsv-antigene
|
CN105055432A
(zh)
*
|
2008-01-25 |
2015-11-18 |
奇默里克斯公司 |
治疗病毒感染的方法
|
PL2176408T3
(pl)
|
2008-01-31 |
2015-08-31 |
Curevac Gmbh |
Kwasy nukleinowe zawierające wzór (NuGiXmGnNv)a i ich pochodne jako środki immunostymulujące/ adiuwanty
|
CN102006891B
(zh)
|
2008-02-13 |
2017-04-26 |
哈佛学院董事会 |
连续的细胞程序化装置
|
WO2009105641A2
(en)
*
|
2008-02-20 |
2009-08-27 |
New York University |
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
|
WO2009114485A2
(en)
|
2008-03-10 |
2009-09-17 |
Children's Hospital & Research Center At Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
EP2265634A2
(de)
|
2008-03-17 |
2010-12-29 |
Intercell AG |
Peptide schutzmittel gegen s. pneumoniae und zusammensetzungen, verfahren und anwendung im zusammenhang damit
|
ES2651924T3
(es)
|
2008-04-18 |
2018-01-30 |
The General Hospital Corporation |
Inmunoterapias que emplean vacunas autoensamblantes
|
JP5727367B2
(ja)
|
2008-05-15 |
2015-06-03 |
ダイナバックス テクノロジーズ コーポレイション |
免疫賦活オリゴヌクレオチドを使用する長期疾患改良
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
CA2826508C
(en)
|
2008-05-23 |
2016-07-19 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
US8703490B2
(en)
|
2008-06-05 |
2014-04-22 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
TWI351288B
(en)
*
|
2008-07-04 |
2011-11-01 |
Univ Nat Pingtung Sci & Tech |
Cpg dna adjuvant in avian vaccines
|
KR101707569B1
(ko)
|
2008-08-01 |
2017-02-16 |
감마 백신즈 피티와이 리미티드 |
인플루엔자 백신
|
EP2385371B1
(de)
|
2008-09-22 |
2014-10-22 |
Oregon Health and Science University |
Verfahren zum Erkennen einer Infektion mit dem Mycobakterium tuberculosis
|
JP5722782B2
(ja)
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
CA2737352C
(en)
*
|
2008-10-16 |
2017-06-27 |
University Of Saskatchewan |
Combination adjuvant formulation
|
US9732324B2
(en)
|
2008-10-23 |
2017-08-15 |
Cornell University |
Anti-viral method
|
WO2010048731A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Christopher John Ong |
Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
US9283184B2
(en)
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
JP5645840B2
(ja)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
リン原子修飾核酸の合成方法
|
CA2745205A1
(en)
|
2008-12-03 |
2010-06-10 |
Protea Vaccine Technologies Ltd. |
Glutamyl trna synthetase (gts) fragments
|
MX2011005915A
(es)
|
2008-12-03 |
2011-08-17 |
Proyecto Biomedicina Cima Sl |
Uso de modulinas solubles en fenol para el desarrollo de vacunas.
|
US8552165B2
(en)
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
DK2376108T3
(en)
|
2008-12-09 |
2017-04-24 |
Pfizer Vaccines Llc |
IgE CH3 peptide vaccine
|
EP2376107B1
(de)
|
2008-12-09 |
2014-05-21 |
Coley Pharmaceutical Group, Inc. |
Immunostimulierende oligonukleotide
|
AU2010203223B9
(en)
|
2009-01-05 |
2015-10-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
HUE025015T2
(en)
|
2009-01-20 |
2016-04-28 |
Transgene Sa |
Soluble in ICAM-1 as a biomarker for predicting therapeutic response
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
WO2010089340A2
(en)
|
2009-02-05 |
2010-08-12 |
Intercell Ag |
Peptides protective against e. faecalis, methods and uses relating thereto
|
US8617574B2
(en)
|
2009-02-13 |
2013-12-31 |
Valneva Austria Gmbh |
Nontypable Haemophilus influenzae antigens
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
US20120039993A1
(en)
|
2009-03-17 |
2012-02-16 |
Glaxosmithkline Biologicals Sa |
Detection of Gene Expression
|
ES2432863T3
(es)
|
2009-03-23 |
2013-12-05 |
Pin Pharma, Inc. |
Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH
|
AU2010227611B2
(en)
|
2009-03-24 |
2014-05-29 |
Transgene Sa |
Biomarker for monitoring patients
|
RU2011144575A
(ru)
|
2009-04-03 |
2013-05-10 |
Эйдженус Инк. |
Способы получения и применения мультишаперон-антигенных комплексов
|
BRPI1010512A2
(pt)
|
2009-04-17 |
2016-03-15 |
Transgène S A |
"método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
|
CA2759332A1
(en)
*
|
2009-04-21 |
2010-10-28 |
Selecta Biosciences, Inc. |
Immunonanotherapeutics providing a th1-biased response
|
CN102413838A
(zh)
|
2009-04-30 |
2012-04-11 |
科勒制药集团有限公司 |
肺炎球菌疫苗及其用途
|
EA201791383A1
(ru)
|
2009-05-27 |
2018-06-29 |
Селекта Байосайенсиз, Инк. |
Наноносители, имеющие компоненты с различными скоростями высвобождения
|
AU2010252012A1
(en)
|
2009-05-27 |
2011-12-22 |
Glaxosmithkline Biologicals S.A. |
CASB7439 constructs
|
WO2010141861A1
(en)
|
2009-06-05 |
2010-12-09 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
JP6110140B2
(ja)
|
2009-06-16 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
ナノエマルションワクチン
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
ES2583257T3
(es)
|
2009-06-24 |
2016-09-20 |
Glaxosmithkline Biologicals S.A. |
Antígenos recombinantes del VSR
|
WO2011005761A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc |
Novel nucleic acid prodrugs and methods use thereof
|
WO2011003905A1
(en)
|
2009-07-10 |
2011-01-13 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
EP3988115A3
(de)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
|
WO2011011519A1
(en)
|
2009-07-21 |
2011-01-27 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
IN2012DN00446A
(de)
|
2009-07-30 |
2015-05-15 |
Pfizer Vaccines Llc |
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
EP2471801A4
(de)
|
2009-08-26 |
2013-12-04 |
Rna Inc |
Aus lipoteichonsäure gewonnene glycolipide und zusammensetzungen damit
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
NZ710626A
(en)
|
2009-09-03 |
2017-03-31 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
US20110229437A1
(en)
*
|
2009-09-17 |
2011-09-22 |
Mutual Pharmaceutical Company, Inc. |
Method of Treating Asthma with Antiviral Agents
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
CA2776922A1
(en)
|
2009-10-07 |
2011-04-14 |
Uvic Industry Partnerships Inc. |
Vaccines comprising heat-sensitive transgenes
|
EP2308896A1
(de)
|
2009-10-09 |
2011-04-13 |
Sanofi-aventis |
Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
|
EP2319871A1
(de)
|
2009-11-05 |
2011-05-11 |
Sanofi-aventis |
Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
|
CN102686611A
(zh)
|
2009-10-09 |
2012-09-19 |
赛诺菲 |
与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
CN102713629B
(zh)
|
2009-11-20 |
2016-02-24 |
俄勒冈健康科学大学 |
用于检测结核分枝杆菌感染的方法
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
US20130034573A1
(en)
|
2009-12-22 |
2013-02-07 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
FR2954703B1
(fr)
|
2009-12-28 |
2013-12-13 |
Chu Nantes |
Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
|
DK2534150T3
(en)
|
2010-02-12 |
2017-06-12 |
Chimerix Inc |
METHODS OF TREATING VIRUS INFECTION
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
US8685416B2
(en)
|
2010-03-02 |
2014-04-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of cancer
|
CA2792258A1
(en)
|
2010-03-05 |
2011-09-09 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
CN103002910A
(zh)
|
2010-03-10 |
2013-03-27 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
WO2011115684A2
(en)
|
2010-03-19 |
2011-09-22 |
Massachusetts Institute Of Technology |
Lipid vesicle compositions and methods of use
|
US9149432B2
(en)
|
2010-03-19 |
2015-10-06 |
Massachusetts Institute Of Technology |
Lipid vesicle compositions and methods of use
|
US20110229556A1
(en)
*
|
2010-03-19 |
2011-09-22 |
Massachusetts Institute Of Technology |
Lipid-coated polymer particles for immune stimulation
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
BR112012024348B1
(pt)
|
2010-03-30 |
2022-11-08 |
Children's Hospital & Research Center At Oakland |
Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
|
US9169325B2
(en)
|
2010-04-13 |
2015-10-27 |
Celldex Therapeutics, Inc. |
Antibodies that bind human CD27 and uses thereof
|
WO2011139709A2
(en)
|
2010-04-26 |
2011-11-10 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
WO2011143653A2
(en)
|
2010-05-14 |
2011-11-17 |
Oregon Health & Science University |
Recombinant hcmv and rhcmv vectors and uses thereof
|
DK2575876T3
(en)
|
2010-05-26 |
2018-03-12 |
Selecta Biosciences Inc |
MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS
|
WO2011148356A1
(en)
*
|
2010-05-28 |
2011-12-01 |
Coley Pharmaceutical Group, Inc. |
Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
|
EP2575868A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige-ch3-peptidimpfstoff
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
ES2558106T3
(es)
|
2010-07-30 |
2016-02-02 |
Curevac Ag |
Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
|
SI2753352T2
(sl)
|
2010-09-03 |
2022-10-28 |
Valneva Austria Gmbh |
Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
|
AR082925A1
(es)
|
2010-09-08 |
2013-01-16 |
Medigene Ag |
Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
US8883171B2
(en)
|
2010-09-14 |
2014-11-11 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
CN103237565B
(zh)
|
2010-10-06 |
2017-10-31 |
哈佛学院董事会 |
用于基于材料的细胞疗法的可注射的成孔水凝胶
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EP2640190A4
(de)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
Modifizierte nikotinische verbindungen und zugehörige verfahren
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
AU2011343368C1
(en)
|
2010-12-14 |
2015-12-24 |
Glaxosmithkline Biologicals S.A. |
Mycobacterium antigenic composition
|
CA2825403C
(en)
|
2011-01-27 |
2023-02-21 |
Gamma Vaccines Pty Limited |
Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
|
US9303070B2
(en)
|
2011-02-22 |
2016-04-05 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
EP2505640A1
(de)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
JP6054942B2
(ja)
|
2011-04-08 |
2016-12-27 |
イミューン デザイン コーポレイション |
免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
US20120288515A1
(en)
|
2011-04-27 |
2012-11-15 |
Immune Design Corp. |
Synthetic long peptide (slp)-based vaccines
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
BR112013030894A2
(pt)
|
2011-06-01 |
2016-08-16 |
Janus Biotherapeutics Inc |
moduladores do sistema imune
|
CA2837207A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
US9107958B2
(en)
|
2011-06-03 |
2015-08-18 |
3M Innovative Properties Company |
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
|
WO2012170356A1
(en)
|
2011-06-04 |
2012-12-13 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
BR112013031564B1
(pt)
|
2011-06-07 |
2021-11-03 |
Ibio, Inc |
Métodos para geração e expressão de um polipeptídio e sistema de expressão
|
WO2012174455A2
(en)
|
2011-06-17 |
2012-12-20 |
University Of Tennessee Research Foundation |
Group a streptococcus multivalent vaccine
|
EP2721158B1
(de)
|
2011-06-20 |
2017-05-03 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Rechnerisch optimierte breit reaktive h1n1-influenza-antigene
|
JP2014527398A
(ja)
|
2011-06-21 |
2014-10-16 |
オンコファクター コーポレイション |
がんの療法および診断のための組成物および方法
|
WO2013007703A1
(en)
*
|
2011-07-08 |
2013-01-17 |
Universität Zürich |
CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
CN109125722A
(zh)
|
2011-07-29 |
2019-01-04 |
西莱克塔生物科技公司 |
产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
EA032475B1
(ru)
|
2011-09-16 |
2019-06-28 |
Юсб Фарма С.А. |
Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение
|
EP2572725B1
(de)
|
2011-09-21 |
2015-07-08 |
Ruprecht-Karls-Universität Heidelberg |
MSI-spezifische Frameshift-Peptide zur Vorbeugung und Behandlung von Krebs
|
WO2013049535A2
(en)
|
2011-09-30 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Influenza vaccine
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
WO2013059493A1
(en)
|
2011-10-20 |
2013-04-25 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
EP2780034A1
(de)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
|
EP2596806A1
(de)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Verfahren zur Vorbeugung einer Dickdarmresektion
|
PE20142295A1
(es)
|
2012-01-16 |
2014-12-19 |
Elizabeth Mckenna |
Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
CN104136456A
(zh)
|
2012-02-07 |
2014-11-05 |
高等教育联邦系统-匹兹堡大学 |
以计算方式优化的h3n2、h2n2和b型流感病毒的广泛反应性抗原
|
EP2811981B1
(de)
|
2012-02-07 |
2019-05-08 |
Infectious Disease Research Institute |
Verbesserte hilfsstoffformulierungen mit tlr4-agonisten und verwendungsverfahren dafür
|
AU2013221877B2
(en)
|
2012-02-13 |
2017-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
EP3492095A1
(de)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
|
ES2773895T3
(es)
|
2012-04-16 |
2020-07-15 |
Harvard College |
Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
|
EP2841098A4
(de)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
Nanopartikel zur behandlung von allergien
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
BR112014028476A2
(pt)
|
2012-05-16 |
2017-08-01 |
Immune Design Corp |
fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
|
IN2014DN09618A
(de)
|
2012-05-23 |
2015-07-31 |
Us Sec Dep Of Health And Human Services |
|
EP2666785A1
(de)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Auf Komplementfaktor C5a basierender Impfstoff
|
US9427476B2
(en)
|
2012-05-24 |
2016-08-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multivalent meningococcal conjugates and methods for preparing conjugates
|
US9687542B2
(en)
|
2012-06-19 |
2017-06-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
WO2014012081A2
(en)
|
2012-07-13 |
2014-01-16 |
Ontorii, Inc. |
Chiral control
|
RU2677639C2
(ru)
|
2012-07-13 |
2019-01-18 |
Шин Ниппон Биомедикал Лэбораториз, Лтд. |
Хиральный адъювант нуклеиновой кислоты
|
EP2872485B1
(de)
|
2012-07-13 |
2020-12-16 |
Wave Life Sciences Ltd. |
Asymmetrische hilfsgruppe
|
PT2879701T
(pt)
|
2012-08-03 |
2024-02-12 |
Access To Advanced Health Inst |
Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
|
WO2014024026A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(de)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 Peptidimpfstoff
|
WO2014037124A1
(en)
|
2012-09-04 |
2014-03-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
EP2898073A4
(de)
|
2012-09-21 |
2016-03-23 |
Elizabeth Mckenna |
Natürlich vorkommende cpg-oligonukleotidzusammensetzungen und therapeutische anwendungen davon
|
EP2912186B1
(de)
|
2012-10-24 |
2021-01-06 |
Platelet Targeted Therapeutics LLC |
Gezielte thrombozytenbehandlung
|
BR112015013737B1
(pt)
|
2012-12-13 |
2021-07-27 |
Ruprecht-Karls-Universitãt Heidelberg |
Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
|
EP3756669A1
(de)
|
2013-01-07 |
2020-12-30 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen zur verwendung zur behandlung von t-zelllymphom
|
JP2016507520A
(ja)
|
2013-01-23 |
2016-03-10 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
安定化されたb型肝炎コアポリペプチド
|
CN105473604B
(zh)
|
2013-03-13 |
2021-01-22 |
美国政府(由卫生和人类服务部的部长所代表) |
融合前rsv f蛋白和其用途
|
US10058603B2
(en)
|
2013-03-15 |
2018-08-28 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
JP2016516754A
(ja)
|
2013-04-03 |
2016-06-09 |
アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーAllertein Therapeutics, LLC |
新規のナノ粒子組成物
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
CA2909721A1
(en)
|
2013-04-19 |
2014-10-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lone star virus
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
WO2014201245A1
(en)
|
2013-06-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
|
CN105579582A
(zh)
|
2013-07-25 |
2016-05-11 |
埃克西奎雷股份有限公司 |
用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
|
EP3632458A1
(de)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
|
EP3030260A1
(de)
|
2013-08-05 |
2016-06-15 |
GlaxoSmithKline Biologicals S.A. |
Immunogene kombinationszusammensetzungen
|
JP6896421B2
(ja)
|
2013-08-21 |
2021-06-30 |
キュアバック アーゲー |
呼吸器合胞体ウイルス(rsv)ワクチン
|
JP7097667B2
(ja)
|
2013-09-27 |
2022-07-08 |
マサチューセッツ インスティテュート オブ テクノロジー |
無担体生物活性タンパク質ナノ構造体
|
WO2015048785A2
(en)
|
2013-09-30 |
2015-04-02 |
Los Alamos National Security, Llc |
Mosaic conserved region hiv immunogenic polypeptides
|
JP2016533352A
(ja)
|
2013-10-04 |
2016-10-27 |
ピーアイエヌ ファーマ インコーポレイテッド |
免疫刺激性HIV Tat誘導体ポリペプチドによる癌の治療
|
WO2015063611A2
(en)
|
2013-11-01 |
2015-05-07 |
University Of Oslo |
Albumin variants and uses thereof
|
EP3524262A1
(de)
|
2013-11-01 |
2019-08-14 |
Pfizer Inc |
Vektoren zur expression von prostataassoziierten antigenen
|
WO2015070207A2
(en)
|
2013-11-11 |
2015-05-14 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
AU2014352986A1
(en)
|
2013-11-20 |
2016-06-16 |
Alk-Abello A/S |
Pan pollen immunogens and methods and uses thereof for immune response modulation
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
MY188100A
(en)
|
2013-11-28 |
2021-11-18 |
Bavarian Nordic As |
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
|
AU2014361788B2
(en)
|
2013-12-13 |
2019-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multi-epitope TARP peptide vaccine and uses thereof
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
PT3089754T
(pt)
|
2013-12-31 |
2021-07-23 |
Infectious Disease Res Inst |
Formulações de vacina de dose única
|
WO2015108048A1
(ja)
*
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
EP3095461A4
(de)
*
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
|
JPWO2015108046A1
(ja)
*
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
CN105934251A
(zh)
|
2014-01-21 |
2016-09-07 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
IL246738B2
(en)
|
2014-01-21 |
2024-08-01 |
Pfizer |
Capsular polysaccharides of Streptococcus pneumoniae and their conjugates
|
RU2771293C2
(ru)
|
2014-01-21 |
2022-04-29 |
Пфайзер Инк. |
Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
|
MA39228A1
(fr)
|
2014-01-21 |
2017-06-30 |
Immune Design Corp |
Compositions à utiliser pour le traitement d'états allergiques
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
US10369216B2
(en)
|
2014-04-01 |
2019-08-06 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
EP3134104B1
(de)
|
2014-04-25 |
2018-12-26 |
Tria Bioscience Corp. |
Synthetische haptenträgerzusammensetzungen und verfahren
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
WO2015184272A2
(en)
|
2014-05-30 |
2015-12-03 |
Sanofi Pasteur Biologics Llc |
Expression and conformational analysis of engineered influenza hemagglutinin
|
EP2952893A1
(de)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Verfahren zur Erkennung von antikörpersezernierenden, HLA-spezifischen B-Zellen
|
PL3164113T3
(pl)
|
2014-06-04 |
2019-09-30 |
Exicure, Inc. |
Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
|
JP6664338B2
(ja)
|
2014-06-13 |
2020-03-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組合せ物
|
WO2016011083A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
EP3398948A3
(de)
|
2014-08-22 |
2018-12-05 |
Janus Biotherapeutics, Inc. |
2,4,6,7-tetrasubstituierte pteridinverbindungen und verfahren zur synthese und verwendung davon
|
EA201790802A1
(ru)
|
2014-10-06 |
2017-08-31 |
Экзикьюр, Инк. |
Соединения против tnf
|
EP4112076A1
(de)
|
2014-10-10 |
2023-01-04 |
The Regents of The University of Michigan |
Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
CA2968531A1
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
AU2015359503B2
(en)
|
2014-12-10 |
2019-05-09 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
CA2971542A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
EP3835312A1
(de)
|
2014-12-31 |
2021-06-16 |
Checkmate Pharmaceuticals, Inc. |
Kombinationstumorimmuntherapie
|
KR102193635B1
(ko)
|
2015-01-09 |
2020-12-21 |
이투빅스 코포레이션 |
복합 면역요법을 위한 방법 및 조성물
|
MX2017009308A
(es)
|
2015-01-15 |
2017-11-08 |
Pfizer |
Composiciones inmunogenicas para usar en vacunas neumococicas.
|
CA3012602A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
US20180036334A1
(en)
|
2015-02-13 |
2018-02-08 |
Icahn School Of Medicine At Mount Sinai |
Rna containing compositions and methods of their use
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
US10647964B2
(en)
|
2015-03-05 |
2020-05-12 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
WO2016154010A1
(en)
|
2015-03-20 |
2016-09-29 |
Makidon Paul |
Immunogenic compositions for use in vaccination against bordetella
|
JP6903046B2
(ja)
|
2015-03-26 |
2021-07-14 |
ジーピーエヌ ワクチン プロプライアタリー リミティド |
連鎖球菌ワクチン
|
CN107708756A
(zh)
|
2015-04-10 |
2018-02-16 |
哈佛学院院长等 |
免疫细胞捕获装置及其制备和使用方法
|
EP3286213B1
(de)
|
2015-04-20 |
2021-08-04 |
Etubics Corporation |
Verfahren und zusammensetzungen für eine kombinationsimmuntherapie
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
SG10201912485PA
(en)
|
2015-05-13 |
2020-02-27 |
Agenus Inc |
Vaccines for treatment and prevention of cancer
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
US10584148B2
(en)
|
2015-06-02 |
2020-03-10 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
WO2016201224A1
(en)
|
2015-06-10 |
2016-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
EP3313376A2
(de)
*
|
2015-06-26 |
2018-05-02 |
Bayer Animal Health GmbH |
Verfahren zur modulation cytosolischer dna-überwachungsmoleküle
|
JP6994453B2
(ja)
|
2015-07-21 |
2022-01-14 |
ファイザー・インク |
コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
|
AU2016305087B2
(en)
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
EP3349717A4
(de)
|
2015-09-17 |
2019-04-17 |
JRX Biotechnology, Inc. |
Ansätze zur verbesserung der hauthydrierung oder -befeuchtung
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
EP3359651A1
(de)
|
2015-10-05 |
2018-08-15 |
THE UNITED STATES OF AMERICA, represented by the S |
Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
WO2017075570A1
(en)
|
2015-10-30 |
2017-05-04 |
The United States Of America, As Represented By Secretary, Department Of Health And Human Sevices |
Compositions and methods for the treatment of her2-expressing solid tumors
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2017120504A1
(en)
|
2016-01-08 |
2017-07-13 |
Durfee Paul N |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
CA3009928A1
(en)
|
2016-01-29 |
2017-08-03 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
|
EP3411475A4
(de)
|
2016-02-06 |
2019-09-11 |
President and Fellows of Harvard College |
Rekapitulation der hämatopoietischen nische zur wiederherstellung der immunität
|
MX2018010961A
(es)
|
2016-03-10 |
2019-03-28 |
Aperisys Inc |
Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada.
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
KR20180127320A
(ko)
|
2016-03-14 |
2018-11-28 |
유니버시티에트 이 오슬로 |
변경된 FcRn 결합을 갖는 조작된 면역글로불린
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
KR102414558B1
(ko)
|
2016-04-18 |
2022-06-29 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd40에 결합하는 효능성 항체 및 이의 용도
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
US11344619B2
(en)
|
2016-05-16 |
2022-05-31 |
Access To Advanced Health Institute |
Formulation containing TLR agonist and methods of use
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
CN109310748A
(zh)
|
2016-05-21 |
2019-02-05 |
传染病研究所 |
用于治疗继发性结核和非结核分枝杆菌感染的组合物和方法
|
KR20190034504A
(ko)
|
2016-05-27 |
2019-04-02 |
이투빅스 코포레이션 |
네오에피토프 백신 조성물 및 이의 사용 방법
|
MX2021010105A
(es)
|
2016-06-01 |
2022-06-16 |
Infectious Disease Res Inst |
Particulas de nanoalumbre que contienen un agente de dimensionamiento.
|
AU2017272344B2
(en)
|
2016-06-02 |
2022-03-03 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
WO2017210592A1
(en)
|
2016-06-03 |
2017-12-07 |
Sanofi Pasteur Inc. |
Modification of engineered influenza hemagglutinin polypeptides
|
BR112018075513A2
(pt)
|
2016-06-13 |
2019-10-01 |
Us Health |
ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
CA3030154A1
(en)
|
2016-07-08 |
2018-01-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric dengue/zika viruses live-attenuated zika virus vaccines
|
WO2018009603A1
(en)
|
2016-07-08 |
2018-01-11 |
The United State of America, as represented by the Secretary, Department of Health and Human Service |
Chimeric west nile/zika viruses and methods of use
|
US11555177B2
(en)
|
2016-07-13 |
2023-01-17 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
BR112019001995A2
(pt)
|
2016-08-05 |
2019-05-07 |
Sanofi Pasteur, Inc. |
composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína
|
CN109862908B
(zh)
|
2016-08-05 |
2023-05-02 |
圣诺菲·帕斯图尔公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
MX2019002178A
(es)
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
EP3554538A2
(de)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
|
US11413344B2
(en)
|
2017-01-20 |
2022-08-16 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US11344629B2
(en)
|
2017-03-01 |
2022-05-31 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
JP2020515587A
(ja)
|
2017-03-31 |
2020-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
免疫原性組成物、使用及び処置方法
|
JP7278259B2
(ja)
|
2017-04-19 |
2023-05-19 |
インスティテュート・フォー・リサーチ・イン・バイオメディシン |
ワクチン及び標的としてのプラスモジウムスポロゾイトnpdpペプチド、新規マラリアワクチン、及びそれに結合する抗体
|
WO2018201090A1
(en)
|
2017-04-28 |
2018-11-01 |
Exicure, Inc. |
Synthesis of spherical nucleic acids using lipophilic moieties
|
CA3066915A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR20240096685A
(ko)
|
2017-06-15 |
2024-06-26 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
US11464845B2
(en)
|
2017-07-21 |
2022-10-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neisseria meningitidis immunogenic compositions
|
WO2019034575A1
(en)
|
2017-08-14 |
2019-02-21 |
Glaxosmithkline Biologicals Sa |
METHODS OF AMPLIFYING IMMUNE RESPONSES
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
JP7285828B2
(ja)
|
2017-09-05 |
2023-06-02 |
トルク セラピューティクス, インコーポレイテッド |
治療用タンパク質組成物ならびにその作製および使用方法
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
AU2018330495A1
(en)
|
2017-09-08 |
2020-03-26 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
EP3678695A1
(de)
|
2017-09-08 |
2020-07-15 |
Infectious Disease Research Institute |
Liposomale formulierungen enthaltend saponin und verwendungsverfahren
|
AU2018359420A1
(en)
|
2017-10-31 |
2020-06-04 |
Kalivir Immunotherapeutics, Inc. |
Platform oncolytic vector for systemic delivery
|
AU2018359558C1
(en)
|
2017-11-03 |
2022-09-22 |
Takeda Vaccines, Inc. |
Method for inactivating Zika virus and for determining the completeness of inactivation
|
EP3703745B1
(de)
|
2017-11-04 |
2024-04-10 |
Nevada Research & Innovation Corporation |
Immunogene konjugate und verfahren zur verwendung davon
|
KR20200098638A
(ko)
|
2017-12-15 |
2020-08-20 |
바이엘 애니멀 헬스 게엠베하 |
면역자극성 올리고뉴클레오티드
|
WO2019126197A1
(en)
|
2017-12-18 |
2019-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
KR20200101954A
(ko)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항원-아주반트 커플링 시약 및 사용 방법
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
CN111629751A
(zh)
|
2018-01-22 |
2020-09-04 |
美国政府(由卫生和人类服务部的部长所代表) |
广泛保护性灭活流感病毒疫苗
|
CN111836639A
(zh)
|
2018-01-26 |
2020-10-27 |
河谷细胞有限公司 |
用于联合癌症疫苗和免疫辅助疗法的组合物和方法
|
EP3752184A1
(de)
|
2018-02-16 |
2020-12-23 |
2A Pharma AB |
Parvovirus-strukturprotein zur behandlung von autoimmunerkrankungen
|
EP3527223A1
(de)
|
2018-02-16 |
2019-08-21 |
2A Pharma AB |
Mutiertes parvovirus-strukturprotein
|
CA3034912A1
(en)
|
2018-02-28 |
2019-08-28 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
ES2973078T3
(es)
|
2018-03-28 |
2024-06-18 |
Sanofi Pasteur Inc |
Métodos de generación de composiciones de vacuna ampliamente protectoras que comprenden hemaglutinina
|
CA3095174A1
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic ospa polypeptides
|
CN112512564A
(zh)
|
2018-04-03 |
2021-03-16 |
赛诺菲 |
铁蛋白蛋白
|
EP3773703A1
(de)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigene influenza-ferriti- polypeptide
|
WO2019195314A2
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
KR20210018206A
(ko)
|
2018-04-03 |
2021-02-17 |
사노피 |
항원성 호흡기 세포융합 바이러스 폴리펩타이드
|
MX2020010410A
(es)
|
2018-04-09 |
2021-01-15 |
Checkmate Pharmaceuticals |
Empaquetado de oligonucleotidos en particulas similares a virus.
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
MX2020012539A
(es)
|
2018-05-23 |
2021-02-16 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos.
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
CN112638936A
(zh)
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
US20210283238A1
(en)
|
2018-08-07 |
2021-09-16 |
Glaxosmithkline Biologicals Sa |
Novel processes and vaccines
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
CN113454100B
(zh)
|
2018-12-04 |
2024-08-23 |
洛克菲勒大学 |
Hiv疫苗免疫原
|
EP3890775A1
(de)
|
2018-12-06 |
2021-10-13 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
EP3893926A1
(de)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
|
US20220023413A1
(en)
|
2018-12-12 |
2022-01-27 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
CN113227125A
(zh)
|
2018-12-12 |
2021-08-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于o-连接的糖基化的修饰的载体蛋白
|
US20220023410A1
(en)
|
2018-12-14 |
2022-01-27 |
University Of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
EP3946446A1
(de)
|
2019-04-02 |
2022-02-09 |
Sanofi |
Antigene multimere polypeptide gegen das respiratorische synzytialvirus
|
WO2020208502A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2020212461A1
(en)
|
2019-04-18 |
2020-10-22 |
Glaxosmithkline Biologicals Sa |
Antigen binding proteins and assays
|
SG11202110646PA
(en)
|
2019-05-20 |
2021-10-28 |
Valneva Se |
A subunit vaccine for treatment or prevention of a respiratory tract infection
|
JP2022532944A
(ja)
|
2019-05-25 |
2022-07-20 |
アクセス ツー アドバンスト ヘルス インスティチュート |
アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
|
EP3980056A4
(de)
|
2019-05-31 |
2023-03-29 |
Universidad De Chile |
Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
|
EP3770269A1
(de)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantifizierung von biokonjugatglykosylierung
|
EP4010014A1
(de)
|
2019-08-05 |
2022-06-15 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzung
|
US20220280491A1
(en)
|
2019-08-30 |
2022-09-08 |
University Of Rochester |
Septin inhibitors for treatment of cancers
|
EP4031251A4
(de)
|
2019-09-18 |
2024-01-10 |
Children's Medical Center Corporation |
Anaplastische lymphomkinase (alk)-krebsimpfstoff und verwendungsverfahren
|
EP3799884A1
(de)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
CN114667343A
(zh)
|
2019-11-01 |
2022-06-24 |
辉瑞大药厂 |
大肠杆菌组合物及其方法
|
US20220396797A1
(en)
|
2019-11-15 |
2022-12-15 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
EP4061412A1
(de)
|
2019-11-22 |
2022-09-28 |
GlaxoSmithKline Biologicals S.A. |
Dosierung und verabreichung eines bakteriellen saccharid-glykokonjugat-impfstoffes
|
WO2021127271A1
(en)
|
2019-12-17 |
2021-06-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Live attenuated leishmania parasite vaccines with enhanced safety characteristics
|
JP7369297B2
(ja)
|
2019-12-17 |
2023-10-25 |
ファイザー・インク |
Cd47、pd-l1に特異的な抗体、およびその使用
|
CN115605498A
(zh)
|
2020-02-23 |
2023-01-13 |
辉瑞公司(Us) |
大肠杆菌组合物及其方法
|
WO2021173907A1
(en)
|
2020-02-28 |
2021-09-02 |
Sanofi Pasteur, Inc. |
High dose influenza vaccine for pediatric subjects
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
JP7407081B2
(ja)
|
2020-07-20 |
2023-12-28 |
三菱重工機械システム株式会社 |
印刷機および印刷機の後片付け方法
|
WO2022051022A1
(en)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
CN116724053A
(zh)
|
2020-09-24 |
2023-09-08 |
弗雷德哈钦森癌症中心 |
靶向sox2抗原的免疫治疗
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
EP4058056A1
(de)
|
2020-10-07 |
2022-09-21 |
Valneva Sweden AB |
Cholera-impfstoffformulierung
|
EP4234585A4
(de)
|
2020-10-23 |
2024-10-02 |
Jiangsu Provincial Center For Disease Control And Prevention Public Health Res Institute Of Jiangsu |
Fusionsprotein und anwendung davon
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
CA3200602A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
EP4243863A2
(de)
|
2020-11-10 |
2023-09-20 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
|
MX2023007648A
(es)
|
2020-12-23 |
2023-08-29 |
Access To Advanced Health Inst |
Adyuvantes de vacuna de solanesol y métodos para prepararlos.
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
US20240299510A1
(en)
|
2020-12-31 |
2024-09-12 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
EP4294433A1
(de)
|
2021-02-22 |
2023-12-27 |
GlaxoSmithKline Biologicals SA |
Immunogene zusammensetzung, verwendung und verfahren
|
US20240156935A1
(en)
|
2021-03-31 |
2024-05-16 |
Vib Vzw |
Vaccine Compositions for Trypanosomatids
|
WO2022217019A1
(en)
|
2021-04-09 |
2022-10-13 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
WO2022214678A2
(en)
|
2021-04-09 |
2022-10-13 |
Valneva Se |
Human metapneumo virus vaccine
|
TW202305125A
(zh)
|
2021-04-30 |
2023-02-01 |
美商凱立凡爾免疫治療股份有限公司 |
用於經修飾mhc表現之溶瘤病毒
|
US20220387613A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
EP4370152A1
(de)
|
2021-07-16 |
2024-05-22 |
The Board Of Trustees Of The University Of Illinois |
Universeller impfstoff für influenzavirus auf basis von tetramerem m2-protein in nanoscheiben
|
US20240335525A1
(en)
|
2021-08-11 |
2024-10-10 |
Sanofi Pasteur Inc. |
Truncated influenza neuraminidase and methods of using the same
|
AU2022361432A1
(en)
|
2021-10-08 |
2024-05-23 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines
|
KR20240107146A
(ko)
|
2021-11-05 |
2024-07-08 |
사노피 |
호흡기 세포융합 바이러스 rna 백신
|
KR20240105412A
(ko)
|
2021-11-05 |
2024-07-05 |
사노피 파스퇴르 인크 |
재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
|
EP4426345A1
(de)
|
2021-11-05 |
2024-09-11 |
Sanofi |
Multivalente hybridinfluenzaimpfstoffe mit hämagglutinin und neuraminidase sowie verfahren zur verwendung davon
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023083964A1
(en)
|
2021-11-11 |
2023-05-19 |
2A Pharma Ab |
Parvovirus structural protein against beta- and gamma-hpv
|
CA3239417A1
(en)
|
2021-11-30 |
2023-06-08 |
Yvonne CHAN |
Human metapneumovirus vaccines
|
KR20240118795A
(ko)
|
2021-11-30 |
2024-08-05 |
사노피 파스퇴르 인크 |
인간 메타뉴모바이러스 바이러스 벡터-기반 백신
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
AU2022413622A1
(en)
|
2021-12-17 |
2024-08-01 |
Sanofi |
Lyme disease rna vaccine
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CN118591621A
(zh)
|
2022-01-27 |
2024-09-03 |
赛诺菲巴斯德有限公司 |
修饰的Vero细胞及其用于病毒生产的方法
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023177579A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
TW202408567A
(zh)
|
2022-05-06 |
2024-03-01 |
法商賽諾菲公司 |
用於核酸疫苗之訊息序列
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2023232901A1
(en)
|
2022-06-01 |
2023-12-07 |
Valneva Austria Gmbh |
Clostridium difficile vaccine
|
WO2024003239A1
(en)
|
2022-06-29 |
2024-01-04 |
Bavarian Nordic A/S |
RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
WO2024094881A1
(en)
|
2022-11-04 |
2024-05-10 |
Sanofi |
Respiratory syncytial virus rna vaccination
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
US20240189410A1
(en)
|
2022-12-13 |
2024-06-13 |
Pfizer Inc. |
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
WO2024149832A1
(en)
|
2023-01-12 |
2024-07-18 |
Bavarian Nordic A/S |
RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
|
WO2024163327A1
(en)
|
2023-01-30 |
2024-08-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024180262A1
(en)
|
2023-03-02 |
2024-09-06 |
Sanofi |
Compositions for use in treatment of chlamydia
|
WO2024186635A2
(en)
|
2023-03-03 |
2024-09-12 |
Celldex Therapeutics, Inc. |
Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
|
WO2024201324A2
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|